Recent research introduces a groundbreaking approach known as duodenal mucosal resurfacing, presenting the first blinded, randomized, sham-controlled evidence indicating that this procedure might provide a safe and enduring solution for maintaining weight loss without the need for continuous medication. This development offers hope for individuals who have experienced weight loss through medications like Ozempic or other GLP-1 therapies.
Lead author Dr. Shelby Sullivan, who directs the Endoscopic Bariatric and Metabolic Program at Dartmouth Health Weight Center and serves as a professor of medicine at the Dartmouth Geisel School of Medicine, emphasizes the significance of this procedure. "While GLP-1 medications are effective, many patients discontinue their use due to factors such as cost, side effects, or the desire to avoid long-term medication. Unfortunately, weight regain is common once these medications are stopped, leading to a loss of metabolic benefits. A treatment that enables patients to cease medication without regaining weight or losing metabolic advantages is a pressing need. Our findings suggest that this minimally invasive procedure may fulfill that need," she stated.
Understanding the "Gut Reset" Procedure
Duodenal mucosal resurfacing is an experimental endoscopic method that employs controlled heat to eliminate damaged tissue from the inner lining of the duodenum, the initial segment of the small intestine. This technique, which burns away unhealthy mucosal layers, promotes the regeneration of new, healthier tissue.
The ongoing REMAIN-1 trial aims to assess whether this rejuvenation of the intestinal lining can instigate a lasting metabolic reset, enabling the body to sustain weight loss after discontinuing medications such as semaglutide or tirzepatide.
Promising Trial Outcomes
Initial results from this trial include data from 45 participants, with 29 receiving the resurfacing treatment and 16 undergoing a sham procedure. All participants had previously lost a minimum of 15% of their body weight using tirzepatide before stopping the drug.
On average, patients lost around 40 pounds while on GLP-1 therapy. Six months post-medication, those in the control group regained significantly more weight, with the sham group regaining approximately 40% more than those who received the actual treatment. Notably, patients who underwent extensive resurfacing regained only about 7 pounds, retaining over 80% of their weight loss, while the control group regained nearly double that amount. The gap between the two groups widened from one to six months after the procedure, indicating that the benefits may not only persist but could also enhance over time.
"What's particularly encouraging is that the benefits seem to increase over time rather than diminish, resembling the effects of medication in terms of dose response," Dr. Sullivan remarked. "This gives us confidence that we are addressing the right biological mechanisms."
Safety and Recovery Insights
The procedure has shown no serious complications, and recovery is generally swift, allowing most patients to resume normal activities within a day. "Aside from recovering from anesthesia, the recovery time is minimal," Dr. Sullivan noted. "Participants could not differentiate between the sham and actual procedure, as symptoms post-treatment are quite mild."
The Role of the Gut in Weight Management
This innovative treatment targets the small intestine, where critical hormones influenced by GLP-1 drugs are produced. Diets high in fat and sugar can alter the duodenal lining, impacting food processing and hormone regulation, which may lead to insulin resistance and metabolic disorders. By restoring a healthier mucosal layer, the procedure aims to reset the body's response to food, stabilizing metabolism at a lower body weight after ceasing medications like Ozempic.
Future Directions
As duodenal mucosal resurfacing remains investigational, the larger REMAIN-1 study includes over 300 participants and is fully enrolled. Researchers anticipate topline six-month data from this pivotal cohort in early Q4 2026, followed by a marketing submission later that year. Dr. Sullivan is set to present the study findings at an upcoming conference.
